Abstracts tagged "Lupus nephritis"

Abstract Number: 931 • 2012 ACR/ARHP Annual Meeting
Health Care Utilization Among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation
Candace H. Feldman¹, Linda T. Hiraki², Graciela S. Alarcon³, Jinoos Yazdany⁴, Jun Liu⁵, Michael A. Fischer⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital/ Harvard School of Public Health, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extreme sociodemographic disparities exist among systemic lupus erythematosus (SLE) patients in the development of end-stage renal disease (ESRD) from lupus nephritis. Better resource allocation…
Abstract Number: 837 • 2012 ACR/ARHP Annual Meeting
Response to MMF Therapy for Lupus Nephritis Is Independent of Genetic Variation of Inosine Monophosphate Dehydrogenase
Noa Schwartz¹, Tejaskumar Patel¹, Ellen M. Ginzler², Neil Solomons³, Jill P. Buyon⁴ and Robert M. Clancy¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ³Vifor Pharma, New York, NY, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: The Aspreva Lupus Management Study (ALMS) demonstrated the efficacy of mycophenolate mofetil (MMF-a prodrug of MFA, mycophenolic acid) for both induction and maintenance of…
Abstract Number: 684 • 2012 ACR/ARHP Annual Meeting
Correlation of Signal Transducers and Activators of Transcription-1 and Microrna-146a with Anaemia and Other Clinical Features in Systemic Lupus Erythematosus Patients
Paul R. Dominguez-Gutierrez¹, Angela Ceribelli¹, Minoru Satoh², Eric S. Sobel³, Yi Li², Westley H. Reeves⁴ and Edward K.L. Chan¹, ¹Oral Biology, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Anaemia is one of the most common haematological manifestations in SLE patients, occurring in about 50% of active cases. STAT1 is a critical signalling…
Abstract Number: 668 • 2012 ACR/ARHP Annual Meeting
Markers of Nitric Oxide and Hydroxyl Radical Formation Are Increased in Proliferative Lupus Nephritis and May Emanate From Increased Nitric Oxide Synthase and NADPH Oxidase Production and Reduced Endothelial Nitric Oxide Synthase-Derived NO Scavenging
Jim Oates¹, Ahmad Mashmoushi¹, Thomas Fleury¹, Ann Hofbauer¹ and Gary S. Gilkeson², ¹Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: The role of redox regulation of cell function in the different International Society of Nephrology/Renal Pathology Society (ISN/RPS) classes of lupus nephritis (LN) is…
Abstract Number: 632 • 2012 ACR/ARHP Annual Meeting
The Effects of Co-Existing Proliferative Histopathology On Membranous Lupus Nephritis
Jennifer L. Graybill¹, Catarina Vila-Inda¹, Chaim Putterman² and Irene Blanco¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) affects up to 60% of SLE patients and is worse in minority communities. Traditionally membranous LN confers a better prognosis than…
Abstract Number: 315 • 2012 ACR/ARHP Annual Meeting
Pediatric Lupus Nephritis: Micrornas – Macro Inflammation
Patrícia Costa Reis¹, Pierre Russo² and Kathleen E. Sullivan³, ¹Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: New biomarkers to guide clinical management of lupus nephritis (LN) patients are highly desirable, since the histopathologic classification currently in use is an unreliable…
Abstract Number: 2249 • 2012 ACR/ARHP Annual Meeting
Comparison of Mycophenolate Mofetil and Intravenous Cyclophosphamide As Induction Therapy in Korean Patients with Lupus Nephritis
Dong-Jin Park¹, Kyung-Eun Lee¹, Tae-Jong Kim¹, Yong-Wook Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: Although intravenous cyclophosphamide (IVC) pulses are generally accepted as standard therapy for induction treatment of active proliferative lupus nephritis (LN), several clinical trials have…
Abstract Number: 306 • 2012 ACR/ARHP Annual Meeting
Children with Probable SLE by ACR Criteria May Need More Aggressive Lupus Treatment Early in the Disease Course
Anjali Patwardhan¹, Igor Dvorchik² and Charles H. Spencer³, ¹Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ²Biostatistics Division, Nationwide Children's Hospital,, Columbus, OH, ³Rheumatology, Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: This research explores whether delay of the childhood-onset SLE (cSLE) diagnosis until 4/11 ACR criteria are met affects patient outcome negatively Methods: Institutional Review…
Abstract Number: 1741 • 2012 ACR/ARHP Annual Meeting
Suppression of Glomerulonephritis in NZB/W F1 Mice by a Selective Inhibitor of Bruton’s Tyrosine Kinase (RN486)
Paola Mina-Osorio¹, Jacob LaStant¹, Natalie Keirstead¹, Toni Whittard¹, Stella Stefanova¹, Alka Patel¹, Jennifer Postelnek¹, John Woods², Soo Min², Yong Kim¹, Julie Demartino², Satwant Narula³ and Daigen Xu¹, ¹Inflammation, Hoffmann-La Roche, Nutley, NJ, ²Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, ³Inflammatory Discovery, Hoffmann-La Roche, Nutley, NJ
Background/Purpose: Bruton tyrosine kinase (Btk) is a Tec family kinase that participates in B cell receptor (BCR), Toll-like Receptor (TLR) and chemokine receptor signaling. It…
Abstract Number: 287 • 2012 ACR/ARHP Annual Meeting
Variation in Healthcare Utilization by Region and Number of Rheumatologists Per State Among Pediatric Medicaid Patients with Lupus Nephritis Prior to End-Stage Renal Disease in the United States, 2000-2004
Linda T. Hiraki¹, Candace H. Feldman², Graciela S. Alarcon³, Jun Liu⁴, Michael A. Fischer⁵, Wolfgang C. Winkelmayer⁶ and Karen H. Costenbader⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁷Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Unequal healthcare access and utilization may contribute to the striking sociodemographic disparities seen in outcomes for children with lupus nephritis. Medicaid is the U.S.…
Abstract Number: 1665 • 2012 ACR/ARHP Annual Meeting
Associations of Race and Ethnicity with Overall Mortality and Cardiovascular Events Among Patients with End-Stage Renal Disease Due to Lupus Nephritis
Jose A. Gomez-Puerta¹, Sushrut Waikar², Graciela S. Alarcon³, Jun Liu⁴, Daniel H. Solomon⁵, Wolfgang C. Winkelmayer⁶ and Karen H. Costenbader⁷, ¹Section of Clinical Sciences, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ²Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁶Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with SLE and lupus nephritis (LN) are at elevated risks of cardiovascular disease. Past studies have suggested that African American patients with SLE…
Abstract Number: 1650 • 2012 ACR/ARHP Annual Meeting
Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy
Jill P. Buyon¹, Aanam Aslam², Marta M. Guerra², Michael D. Lockshin³, Carl A. Laskin⁴, Ware Branch⁵, Lisa R. Sammaritano⁶, Michelle Petri⁷, Joan T. Merrill⁸, Allen D. Sawitzke⁹ and Jane E. Salmon⁶, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁵Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT
Background/Purpose: Renal disease is a critical concern of physicians counseling lupus patients regarding pregnancy. In patients without a history of kidney disease, does pregnancy increase…
Abstract Number: 1444 • 2012 ACR/ARHP Annual Meeting
HLA-DR3 Controls Autoantibody Response to Sm in NZM2328.DR3+.AE0 Transgenic Mice
Vaidehi R. Chowdhary¹, Chao Dai², Shu Man Fu² and Chella S. David³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Medicine/CIIR/Rheumatology, University of Virginia Health System, Charlottesville, VA, ³Departement of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Large genome wide scans have confirmed the strong association of HLA -DR3 with risk of developing SLE and antibody response to Sm which is specific…
Abstract Number: 1433 • 2012 ACR/ARHP Annual Meeting
Persistent Dyslipidemia Is a Risk Factor of Progression to Chronic Kidney Disease in Patients with Lupus Nephritis
Dong-Jin Park¹, Kyung-Eun Lee¹, Tae-Jong Kim¹, Yong-Wook Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: To investigate the effect of dyslipidemia at baseline and during follow-up period on the progression to chronic kidney disease (CKD) in patients with biopsy-proven…
Abstract Number: 1413 • 2012 ACR/ARHP Annual Meeting
Clinical Presentation, Treatment and Outcome of Membranous Nephropathy in SLE: A Comparison with Proliferative Lupus Glomerulonephritis in 141 Patients
Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the presentation and outcome of membranous nephropathy in SLE in comparison with proliferative lupus glomerulonephritis. Methods: Patients with biopsy firmed active lupus nephritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].